China Life Private Equity Investment
VC Fund
Beijing, China
China Life Private Equity Investment is a equity investment platform.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries China Life Private Equity Investment invests in
Stages China Life Private Equity Investment invests in
Countries China Life Private Equity Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $29M–$142M
- Series B
- $42M–$718M
- Series C
- $4.3M–$283M
Investment Focus
Industry
- Biotechnology 10 (28%)
- Health Care 8 (22%)
- Biopharma 7 (19%)
- Manufacturing 6 (17%)
- Pharmaceutical 6 (17%)
Stage
- Series C 11 (31%)
- Series B 7 (19%)
- Series A 3 (8%)
- Series D 3 (8%)
- Funding Round 2 (6%)
Country
- China 22 (61%)
- United States 2 (6%)
- Japan 1 (3%)
- Malaysia 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Wan Yiqing
President
|
President | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
NNB Nutrition is a technology company devoted to the study, creation, manufacture, and marketing of novel nutritious raw materials. They processing mode to develop and produce innovative raw materials for international partners. NNB consistently focuses on using technical innovation as its core productivity, fully assuring product quality, anddevoting itself to developing components for human health in today's thriving health business. | $29.5M / Series C / Jul 13, 2026 | |
|
|
Sudu Technology is a high-tech enterprise specializing in the research and development of general-purpose robot brains, focusing on building advanced cognitive architectures that integrate perception, decision-making, and control, enabling robots to operate autonomously across diverse environments and tasks while continuously learning and adaptingthrough real-world interactions. | Series A / Apr 20, 2026 | |
|
|
Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment. | $29M / Series A / Apr 02, 2026 | |
|
|
The goal of Stepstar is to "Ten Times the Possibility of Everyone" through Intelligent Step. Step Star firmly creates its own super model and actively uses important resources like | $718.1M / Series B / Jan 26, 2026 | |
|
|
Chaoqun Testing Technology is an X-ray equipment manufacturer that focuses on the design and manufacturing of industrial and medical X-ray tubes, sources, and systems. | $70.2M / Venture - Series Unknown / Oct 24, 2025 | |
|
|
SJ Semi is a MEOL (Middle-End of Line) foundry which implements front-end wafer manufacturing and quality systems to MEOL operations. SJSemi's main business is providing bumping, Cu pillar, RDL, and testing services for 12" wafers. The company also places heavy R&D emphasis on fan-out, TSV, interposer, and 3D technologies. | $700M / Venture - Series Unknown / Dec 31, 2024 | |
|
|
Autolink is a vehicle intelligent terminal solution provider. | Series D / May 24, 2024 | |
|
|
Xindi Digital Engineering System specializes in the development of 3D CAD software for manufacturing enterprises. | Series D / Jan 25, 2024 | |
|
|
Weikaier Pharmaceutical provides R&D of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals. | $63.4M / Series C / Jan 02, 2024 | |
|
|
Astronergy specializes in cutting-edge research, development and production of solar modules. It is the first large scale producer of high-efficiency thin film PV modules in mainland China, and has been a trusted provider of monocrystalline and polycrystalline PV modules since its founding in 2006. | $283.5M / Series C / Jul 25, 2023 | |
| See all 36 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does China Life Private Equity Investment invest in?
China Life Private Equity Investment invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series C and Series B stage. Most of the 36 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is China Life Private Equity Investment's check size?
China Life Private Equity Investment typically joins rounds of $29M–$142M at Series A, $42M–$718M at Series B and $4.3M–$283M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds China Life Private Equity Investment participates in.
How do I contact China Life Private Equity Investment?
Public channels for China Life Private Equity Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at China Life Private Equity Investment?
The team at China Life Private Equity Investment includes Wan Yiqing (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!